Publications

5532 Results

A randomized investigation of high-dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia.

Authors
J Weick;K Kopecky;FR Appelbaum;D Head;L Elias;L Kingsbury;D Daniels;SP Balcerzak;GM Mills;HE Hynes;CA Coltman Jr;M Grever
Journal / Conference
ASCO 11:261(#856)
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8600

Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside.

Authors
CL Willman;KJ Kopecky;J Weick;FR Appelbaum;MR Grever;DR Head;L Elias;SP Balcerzak;GM Mills;HE Hynes
Journal / Conference
ASCO 11:262(#857)
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8600

Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with cyclosporin-A (CSA).

Authors
AF List;C Spier;J Greer;C Azar;J Hutter;S Wolff;S Salmon
Journal / Conference
ASCO 11:264(#866)
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8600

Quantitative PCR analysis of MDR1 mRNA in patients with multiple myeloma.

Authors
BW Futscher;LL Blake;TM Grogan;WS Dalton
Journal / Conference
AACR 33:467(#2792)
Year
1992
Research Committee(s)
Myeloma
Study Number(s)
SWOG-8624

Impact of glucocorticoids (GC) and interferon (IFN) on outcome in multiple myeloma.

Authors
SE Salmon;J Crowley
Journal / Conference
ASCO 11:316(#1069)
Year
1992
Research Committee(s)
Myeloma
Study Number(s)
SWOG-8624

A randomized comparison of deoxycofomycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): An NCI-sponsored intergroup study. (SWOG, ECOG, CALGB, NCIC-CTG).

Authors
M Grever;K Kopecky;D Head;P Cassileth;H Golomb;T Habermann;K Rai;E Eisenhauer;B Cheson
Journal / Conference
ASCO 11:264(#868)
Year
1992
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8691 (INT-0073)

A phase II trial of trimetrexate in the treatment of esophageal cancer: A Southwest Oncology Group trial.

Authors
T Brown;T Fleming;C Tangen;J Macdonald
Journal / Conference
ASCO 11:166(#479)
Year
1992
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-8721

Adjuvant radiotherapy following radical prostatectomy for pathologic stage C adenocarcinoma of the prostate: Initial evaluation of toxicity.

Authors
I Thompson;ED Crawford;G Miller;J Paradelo;B Blumenstein;M Wolf;C Moinpour;K Hayden
Journal / Conference
ASCO 11:212(#663)
Year
1992
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8794

Phase II trial of echinomycin in advanced renal cell carcinoma: A Southwest Oncology Group study.

Authors
ME Marshall;S Taylor;M Wolf;R Flanigan;B Blumenstein;ED Crawford
Journal / Conference
ASCO 11:206(#637)
Year
1992
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8802

The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group (SWOG).

Authors
PA Bunn;J Crowley;M Hazuka;R Tolley;R Livingston
Journal / Conference
ASCO 11:292(#974)
Year
1992
Research Committee(s)
Lung
Study Number(s)
SWOG-8812